ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,222.68
0.16%
US Tech 100
17,650.00
0.05%
다우존스 지수
39,512.84
0.32%
Bitcoin
60,952.70
-0.81%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 유럽
  5. EU
  6. Vivoryon Therapeut (VVY)

  7. Vivoryon Therapeut (VVY) 뉴스

VVY

Vivoryon Therapeut (VVY)

Vivoryon Therapeut
일자:
정렬 기준:
 검색 관련기사 보기:EU:VVY
일자시간출처헤드라인심볼기업
2024/05/0814:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024EU:VVYVivoryon Therapeut
2024/04/2414:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic UpdatesEU:VVYVivoryon Therapeut
2024/04/1614:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024EU:VVYVivoryon Therapeut
2024/03/1515:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Changes to Board CompositionEU:VVYVivoryon Therapeut
2024/03/0415:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s DiseaseEU:VVYVivoryon Therapeut
2024/01/0815:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024EU:VVYVivoryon Therapeut
2023/12/0615:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressEU:VVYVivoryon Therapeut
2023/11/2815:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023EU:VVYVivoryon Therapeut
2023/11/0715:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Present at Upcoming Investor ConferenceEU:VVYVivoryon Therapeut
2023/11/0715:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Present at Upcoming Investor ConferenceEU:VVYVivoryon Therapeut
2023/10/2614:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose DecisionEU:VVYVivoryon Therapeut
2023/10/2314:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated DoseEU:VVYVivoryon Therapeut
2023/10/2314:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated DoseEU:VVYVivoryon Therapeut
2023/10/1722:32GlobeNewswire Inc.Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion LeadersEU:VVYVivoryon Therapeut
2023/10/1722:32GlobeNewswire Inc.Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion LeadersEU:VVYVivoryon Therapeut
2023/10/0514:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference ParticipationEU:VVYVivoryon Therapeut
2023/10/0514:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference ParticipationEU:VVYVivoryon Therapeut
2023/09/1520:57GlobeNewswire Inc.Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the BoardEU:VVYVivoryon Therapeut
2023/09/0714:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational ProgressEU:VVYVivoryon Therapeut
2023/08/3114:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023EU:VVYVivoryon Therapeut
2023/08/0506:35GlobeNewswire Inc.Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023EU:VVYVivoryon Therapeut
2023/08/0506:30GlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive OfficerEU:VVYVivoryon Therapeut
2023/07/1616:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s DiseaseEU:VVYVivoryon Therapeut
2023/06/2201:02GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General MeetingEU:VVYVivoryon Therapeut
2023/06/1600:49GlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces CEO Transition PlanEU:VVYVivoryon Therapeut
2023/06/0114:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Participate in Upcoming ConferencesEU:VVYVivoryon Therapeut
2023/05/2614:39GlobeNewswire Inc.Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 MillionEU:VVYVivoryon Therapeut
2023/05/2600:50GlobeNewswire Inc.Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild OfferingEU:VVYVivoryon Therapeut
2023/05/1614:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational ProgressEU:VVYVivoryon Therapeut
2023/05/0914:02GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023EU:VVYVivoryon Therapeut
 검색 관련기사 보기:EU:VVY

최근 히스토리

LSE
0GZB
Probi Ab
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유